- Yang H, Breyer BN, Rimm EB, Giovannucci E, Loeb S, Kenfield SA, Bauer SR.
“Plant-based diet index and erectile dysfunction in the Health Professionals Follow-Up Study.”
British Journal of Urology International. epub 2022 Apr 28. PMID: 35484829.
Link: https://pubmed.ncbi.nlm.nih.gov/35484829/
A healthy plant-based diet is associated with a lower risk of erectile dysfunction for men ages 60-70. Encouraging a healthy plant-based diet is an environmentally-friendly intervention for men interested in maintaining erectile function..
- Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P
“Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.”
Journal of Clinical Oncology 2017;35(13):1430-1436. PMID: 28447913.
Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913
The relationship between testosterone replacement therapy and prostate cancer risk is controversial. We found no association between testosterone therapy and overall prostate cancer risk. Long-term testosterone therapy was associated with a significantly reduced risk of aggressive prostate cancer.
- Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P.
“Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.“
European Urology. 2015 Dec 29 epub. PMID: 26743040
Link: http://www.ncbi.nlm.nih.gov/pubmed/26743040
A previous study from Germany reported a significantly increased risk of prostate cancer recurrence in men taking phosphodiesterase type 5 (PDE5) inhibitors after radical prostatectomy, which was subsequently refuted in an Italian study. We followed up on this issue using nationwide Swedish registry data, and confirmed that there is no association between PDE5 inhibitors with prostate cancer recurrence after treatment.
- Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.
“Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”
JAMA 2015; 313: 2449-55. PMID: 26103029.
Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029
A recent study suggested a possible link between phosphodiesterase inhibitors used for erectile dysfunction and risk of malignant melanoma. Through a large collaboration with the national registries of Sweden, we performed a large study that raised questions about a causal relationship including lack of a dose-response relationship. Instead, the observed association between erectile dysfunction drugs and melanoma likely reflects shared risk factors including lifestyle and socioeconomic status.
-
Loeb S, Ventimiglia E, Salonia A, Folkvaljon Y, Stattin P.
“Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma.”
J Natl Cancer Inst. 2017 Aug 1;109(8). PMID: 29117385
-
Loeb S, Stattin P.
“Further Evidence against a Causal Association between Erectile Dysfunction Drugs and Melanoma.”
European Urology 2016 Jul 16 epub. PMID: 27436160.
-
Loeb S, Lambe M, Stattin P.
“Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D.F. Penson J Urol 2015; 194: 1710-1711.”
Journal of Urology 2016 epub. PMID: 26783933